Department of Medicine-Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK.
Exerc Sport Sci Rev. 2022 Oct 1;50(4):222-229. doi: 10.1249/JES.0000000000000303.
Approximately 6 million individuals have heart failure in the United States alone and 15 million in Europe. Left ventricular assist devices (LVAD) improve survival in these patients, but functional capacity may not fully improve. This article examines the hypothesis that patients supported by LVAD experience persistent reductions in functional capacity and explores mechanisms accounting for abnormalities in exercise tolerance.
仅在美国,就有约 600 万人患有心力衰竭,在欧洲则有 1500 万人。左心室辅助装置(LVAD)可提高这些患者的生存率,但功能能力可能无法完全改善。本文研究了 LVAD 支持的患者持续存在功能能力下降的假设,并探讨了导致运动耐量异常的机制。